AMRN — what changed in the latest 10-Q
A section-by-section comparison of AMRN's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-07-29 vs the prior 10-Q · 2026-04-29
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +42 | −15 | ~34 | 45 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 2 |
| Legal proceedings | Text added/removed | 0 | 0 | ~1 | 0 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | 0 | 0 | ~1 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-07-29
(3) Magnapharm will be the sole and exclusive distributor of VAZKEPA in the Romanian territory to import, register, distribute and commercialize VAZKEPA.
In April 2026, the European Federation of Internal Medicine released Assessment and Management of Cardiovascular–Kidney–Liver Metabolic-Syndrome in the Primary Care Setting: A Multidisciplinary Consensus Statement, in the European Journal of Internal Medicine. This stated that treatment of elevated …
In May 2026, the American Heart Association, or AHA, released a 2026 Scientific Statement update on the Secondary Prevention After Coronary Artery Bypass Graft Surgery, which stated that as a third line therapy if the combination of statin and ezetimibe still fails to achieve the target Low-Density …
In June 2026, the American College of Cardiology/AHA Joint Committee released a report; the 2026 AHA/American College of Cardiology, or ACC/American Diabetes Association, or ADA/American Society of Nephrology, or ASN, Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascu…
In May 2026, at the Digestive Disease Week meeting in Chicago, IL, researchers from Harvard working on an Amarin supported investigator-initiated trial presented data at a poster session. The poster presentation included data on the effect of IPE treatment on fecal metabolites and microbiome among p…
Text removed vs the prior filing · source: 10-Q · 2026-04-29
In January 2026, the American Diabetes Association, or ADA, released guidelines on Cardiovascular Disease and Risk Management in Standards of Care in Diabetes that stated that in individuals with Atherosclerotic Cardiovascular Disease, or ASCVD, or other CV risk factors on a statin with managed LDL-…
In January 2026, the Egyptian Heart Journal published the 2025 Egyptian guidelines for the management of dyslipidemia stating that LDL-C-lowering therapies reduce ASCVD risk regardless of TG level and in statin-treated patients with TG 135–499 mg/dL, IPE (2 g twice daily) is recommended.
In March 2026, the American College of Cardiology/American Heart Association/Multi-society Dyslipidemia Guidelines were released. These guidelines recognize that elevated TG levels contribute meaningfully to CV disease burden and
ongoing CV events even in patients achieving LDL-C targets, underscoring the need for complementary therapeutic approaches beyond statin monotherapy to further reduce risk in high and very high-risk populations. IPE is the only primary TG-lowering medication that reduces ASCVD event risk in combinat…
In March 2026, the ESC Council on Basic Cardiovascular Science, or CBCS, and associated working groups, released a scientific statement on novel CV metabolic risk factor mechanisms and therapeutic opportunities, in the European Heart Journal. The statement noted that not only does IPE cause substant…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice